Amivantamab plus Chemotherapy for EGFR+ NSCLC After Osimertinib

Currently, patients with EGFR-mutant non–small-cell lung cancer (NSCLC) are generally treated with platinum-based chemotherapy after progression on osimertinib. Unfortunately, durations of response are short. In an effort to improve outcomes, researchers conducted an industry-funded, open-label, phase 3 trial in which 657 patients with progression on osimertinib were randomized to receive amivantamab plus lazertinib plus chemotherapy, chemotherapy alone, or amivantamab plus chemotherapy.

After excess hematologic toxicity was noted in the amivantamab-lazertinib-chemotherapy arm, lazertinib was started after the completion of chemotherapy. As the investigators thought amivantamab would not have significant central nervous system penetration, t…